Matsumoto K, Shishido H, Uzuka Y, Nagatake T, Yamamoto M, Sakuma Y, Maezawa I, Yamaguchi T
Jpn J Antibiot. 1985 Oct;38(10):2699-715.
Aspoxicillin (ASPC), a new injectable semisynthetic penicillin, was administered to healthy volunteers to elucidate its safety and pharmacokinetics. No abnormalities obviously attributable to ASPC were observed in the examinations covering subjective and objective symptoms, blood pressure, heart rate, respiratory rate, electrocardiogram and body temperature, as well as in hematology, blood chemistry and urinalysis. There were slight increase in LDH (1 case), Al-P (1 case) and blood-glucose levels (2 cases) at 2 or 4 weeks after the administration with intravenous bolus consecutive injection (1 g X 1 or 2/day, 8 to 10 times), but these increases were not considered to be attributable to ASPC. When ASPC was administered by consecutive intravenous bolus injection, there observed no tendency of accumulation of the drug in serum or urine. When 1 g of ASPC was given intramuscular (i.m.), intravenous injection (i.v.) and intravenous drip infusion (d.i.) route, the maximum antibiotic levels in serum reached 25.2 micrograms/ml, 118.2 micrograms/ml and 70.3 micrograms/ml at 0.75 hour, 0.08 hour and 1 hour after the administration, respectively. The biological half-lives of ASPC attained by these 3 different routes were as follows: 1.73 hours (i.m.), 1.65 hours (i.v.) and 1.44 hours (d.i.). In a cross-over test with piperacillin (PIPC), serum levels of ASPC were higher than those of PIPC and half-lives of ASPC were longer. The 8 hours urinary recovery of ASPC was 75.9% after intravenous injection, 74.6% after intramuscular injection and 88.0% after intravenous drip infusion. Most of urinary recovery was excreted within 4 hours after administration regardless of dose levels, frequency of dosing or administration route. Thin layer chromatographic bioautography was conducted with the samples of serum and urine collected from subjects received ASPC. No antibacterial metabolite was observed in the serum obtained 2 hours after administration but a metabolite identified as amoxicillin was detected in a part of urine samples collected after 8 to 10 hours after the injection.
阿扑西林(ASPC)是一种新型注射用半合成青霉素,对健康志愿者进行给药以阐明其安全性和药代动力学。在涵盖主观和客观症状、血压、心率、呼吸频率、心电图和体温以及血液学、血液化学和尿液分析的检查中,未观察到明显归因于ASPC的异常情况。在连续静脉推注(1g×1或2/天,8至10次)给药后2周或4周时,乳酸脱氢酶(1例)、碱性磷酸酶(1例)和血糖水平(2例)有轻微升高,但这些升高不被认为归因于ASPC。当通过连续静脉推注给予ASPC时,未观察到药物在血清或尿液中有蓄积倾向。当以1g的剂量通过肌内(i.m.)、静脉注射(i.v.)和静脉滴注(d.i.)途径给予ASPC时,给药后0.75小时、0.08小时和1小时血清中的最大抗生素水平分别达到25.2微克/毫升、118.2微克/毫升和70.3微克/毫升。通过这三种不同途径获得的ASPC的生物半衰期如下:1.73小时(i.m.)、1.65小时(i.v.)和1.44小时(d.i.)。在与哌拉西林(PIPC)的交叉试验中,ASPC的血清水平高于PIPC,且ASPC的半衰期更长。静脉注射后ASPC的8小时尿回收率为75.9%,肌内注射后为74.6%,静脉滴注后为88.0%。无论剂量水平、给药频率或给药途径如何,大部分尿回收率在给药后4小时内排出。对接受ASPC的受试者采集的血清和尿液样本进行了薄层色谱生物自显影。给药后2小时获得的血清中未观察到抗菌代谢物,但在注射后8至10小时采集的部分尿液样本中检测到一种鉴定为阿莫西林的代谢物。